Revance Therapeutics, Inc.

NasdaqGM:RVNC Stock Report

Market Cap: US$357.7m

Revance Therapeutics Management

Management criteria checks 2/4

Revance Therapeutics' CEO is Mark Foley, appointed in Oct 2019, has a tenure of 5.25 years. total yearly compensation is $10.07M, comprised of 7.2% salary and 92.8% bonuses, including company stock and options. directly owns 1.06% of the company’s shares, worth $3.78M. The average tenure of the management team and the board of directors is 5.5 years and 5.5 years respectively.

Key information

Mark Foley

Chief executive officer

US$10.1m

Total compensation

CEO salary percentage7.2%
CEO tenure5.3yrs
CEO ownership1.1%
Management average tenure5.5yrs
Board average tenure5.5yrs

Recent management updates

Recent updates

Revance Therapeutics: Crown Merger Red Flags Makes For Problematic Call On Shares

Sep 26

Revance Therapeutics: Problems Mounting Amid Legal And Financial Woes

Jun 20

What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You

Mar 04
What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You

Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain

Feb 29

Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%

Dec 28
Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%

Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be

Nov 10
Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be

Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt

Aug 10
Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt

Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors

Jun 14
Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors

Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

Apr 17
Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt

Jan 02
Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt

Revance Therapeutics submits sBLA for Daxxify for cervical dystonia

Oct 20

CEO Compensation Analysis

How has Mark Foley's remuneration changed compared to Revance Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$303m

Jun 30 2024n/an/a

-US$304m

Mar 31 2024n/an/a

-US$325m

Dec 31 2023US$10mUS$720k

-US$324m

Sep 30 2023n/an/a

-US$292m

Jun 30 2023n/an/a

-US$337m

Mar 31 2023n/an/a

-US$341m

Dec 31 2022US$7mUS$673k

-US$356m

Sep 30 2022n/an/a

-US$274m

Jun 30 2022n/an/a

-US$263m

Mar 31 2022n/an/a

-US$274m

Dec 31 2021US$7mUS$660k

-US$281m

Sep 30 2021n/an/a

-US$297m

Jun 30 2021n/an/a

-US$303m

Mar 31 2021n/an/a

-US$292m

Dec 31 2020US$9mUS$650k

-US$282m

Sep 30 2020n/an/a

-US$249m

Jun 30 2020n/an/a

-US$209m

Mar 31 2020n/an/a

-US$186m

Dec 31 2019US$18mUS$190k

-US$159m

Sep 30 2019n/an/a

-US$155m

Jun 30 2019n/an/a

-US$146m

Mar 31 2019n/an/a

-US$143m

Dec 31 2018US$243kn/a

-US$143m

Compensation vs Market: Mark's total compensation ($USD10.07M) is above average for companies of similar size in the US market ($USD2.26M).

Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.

CEO

Mark Foley (59 yo)

5.3yrs

Tenure

US$10,068,915

Compensation

Mr. Mark J. Foley serves as Chairman of uLab Systems, Inc. He has been Chief Executive Officer at Revance Therapeutics, Inc. since October 13, 2019 and served as its President since October 13, 2019 until...

Leadership Team

NamePositionTenureCompensationOwnership
Mark Foley
CEO & Director5.3yrsUS$10.07m1.06%
$ 3.8m
Tobin Schilke
CFO & Principal Accounting Officer6.2yrsUS$3.97m0.093%
$ 334.2k
Dwight Moxie
Chief Legal Officer & General Counsel4.9yrsUS$3.53m0.046%
$ 163.0k
Jessica Serra
Head of Investor Relations & ESGno datano datano data
Jeanie Herbert
Senior Director of Investor Relations & Corporate Communications8.1yrsno datano data
Taryn Conway
Vice President of Marketing5.8yrsno datano data
Amie Krause
Chief People Officer1.8yrsno datano data
Conor Gallagher
Head of Medical Affairs & Aesthetics6.7yrsno datano data
David Hollander
Chief Medical Officer of Global Therapeutics Franchise Lead2yrsno data0.10%
$ 357.9k
Erica Jordan
Chief Commercial Officerno datano data0.11%
$ 391.7k

5.5yrs

Average Tenure

49yo

Average Age

Experienced Management: RVNC's management team is seasoned and experienced (5.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mark Foley
CEO & Director7.3yrsUS$10.07m1.06%
$ 3.8m
Angus Russell
Independent Chairman10.8yrsUS$346.03k0.049%
$ 175.6k
Jill Beraud
Independent Director5.6yrsUS$317.53k0.042%
$ 148.7k
Julian Gangolli
Independent Director8.5yrsUS$305.03k0.043%
$ 153.8k
Vladimir Coric
Independent Director1.8yrsUS$421.49k0.020%
$ 70.9k
Olivia Ware
Independent Director3.8yrsUS$295.03k0.030%
$ 108.0k
Carey Kolaja
Independent Director3.8yrsUS$304.18k0.030%
$ 107.6k
Christian Nolet
Independent Director5.5yrsUS$315.03k0.042%
$ 148.7k

5.5yrs

Average Tenure

65yo

Average Age

Experienced Board: RVNC's board of directors are considered experienced (5.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 00:19
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Revance Therapeutics, Inc. is covered by 21 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Balaji PrasadBarclays
Balaji PrasadBarclays
David MarisBMO Capital Markets Equity Research